Unknown

Dataset Information

0

Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design.

ABSTRACT: Biophysical fragment screening of a thermostabilized β1-adrenergic receptor (β1AR) using surface plasmon resonance (SPR) enabled the identification of moderate affinity, high ligand efficiency (LE) arylpiperazine hits 7 and 8. Subsequent hit to lead follow-up confirmed the activity of the chemotype, and a structure-based design approach using protein-ligand crystal structures of the β1AR resulted in the identification of several fragments that bound with higher affinity, including indole 19 and quinoline 20. In the first example of GPCR crystallography with ligands derived from fragment screening, structures of the stabilized β1AR complexed with 19 and 20 were determined at resolutions of 2.8 and 2.7 Å, respectively.

SUBMITTER: Christopher JA 

PROVIDER: S-EPMC3654563 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design.

Christopher John A JA   Brown Jason J   Doré Andrew S AS   Errey James C JC   Koglin Markus M   Marshall Fiona H FH   Myszka David G DG   Rich Rebecca L RL   Tate Christopher G CG   Tehan Benjamin B   Warne Tony T   Congreve Miles M  

Journal of medicinal chemistry 20130409 9

Biophysical fragment screening of a thermostabilized β1-adrenergic receptor (β1AR) using surface plasmon resonance (SPR) enabled the identification of moderate affinity, high ligand efficiency (LE) arylpiperazine hits 7 and 8. Subsequent hit to lead follow-up confirmed the activity of the chemotype, and a structure-based design approach using protein-ligand crystal structures of the β1AR resulted in the identification of several fragments that bound with higher affinity, including indole 19 and  ...[more]

Similar Datasets

Unknown Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery.
| S-EPMC3740835 | biostudies-literature
Unknown Novel starting points for fragment-based drug design against mycobacterial thioredoxin reductase identified using crystallographic fragment screening.
| S-EPMC10478635 | biostudies-literature
Unknown Novel starting points for fragment-based drug design against human heat-shock protein 90 identified using crystallographic fragment screening.
| S-EPMC11878448 | biostudies-literature
Unknown Integrating Protein Interaction Surface Prediction with a Fragment-Based Drug Design: Automatic Design of New Leads with Fragments on Energy Surfaces.
| S-EPMC9832486 | biostudies-literature
Unknown Hybrid neural network approaches to predict drug-target binding affinity for drug repurposing: screening for potential leads for Alzheimer's disease.
| S-EPMC10334190 | biostudies-literature
Transcriptomics Developing novel flavonoid senolytics through phenotypic drug screening and drug design
2024-10-27 | GSE279349 | GEO
Unknown Fragment screening of cyclin G-associated kinase by weak affinity chromatography.
| S-EPMC3475971 | biostudies-literature
Unknown New leads for fragment-based design of rhenium/technetium radiopharmaceutical agents.
| S-EPMC5414402 | biostudies-literature
Unknown Innovative Approach for a Classic Target: Fragment Screening on Trypanothione Reductase Reveals New Opportunities for Drug Design.
| S-EPMC9289546 | biostudies-literature
Unknown Screening of β1- and β2-Adrenergic Receptor Modulators through Advanced Pharmacoinformatics and Machine Learning Approaches.
| S-EPMC8538848 | biostudies-literature